ALS Worldwide welcomes any questions or comments you might have.  We provide free, personalized and confidential support services to anyone in the ALS community—whether you are a patient or a loved one, friend, health care professional or caregiver of someone diagnosed.

Get help now! Fill out the Online Profile Form or if you would prefer to talk with someone by email or phone first, please contact us at [email protected] or 1-608-663-0920.

For all other inquiries, please use the email form to the right and we will respond promptly to your request.Thank you.

ALS Worldwide
5808 Dawley Drive
Fitchburg, WI 53711‑7209

ALS Worldwide
February 16, 2016

MicroNeurotrophin Drug Development: Key Steps

Development (2005-2014)
MicroNeurotrophin drugs were discovered and developed by Professor Achilleas Gravanis and his scientific colleagues at the University of Crete in Greece.


Preclinical ALS Research (January-October 2015)
While in vivo (animal) or in vitro (cell culture) models remain challenging as a reliable method to predict a drug’s effectiveness for humans with disease like ALS, these FDA required tests by FDA have been completed.

Most importantly, in preclinical trials, MicroNeurotrophin drugs appear to protect and strengthen the nerve cells affected by ALS in both animal and cell models, without showing any signs of toxicity or harmful side effects.


FDA Required Independent Safety Studies (2-3 months)
Cost: $1,875,000 – FUNDING REQUIRED
Before clinical trials may begin in humans, the FDA requires confirmation that the new drug is safe in animals. These expensive safety studies must be conducted by an independent FDA-approved Contract Research Organization (CRO) that follows strict guidelines to ensure the integrity of the safety tests on MicroNeurotrophins.

Phase 1 Investigational New Drug (IND) Trial (6 months)
Cost: $2,000,000 –

MicroNeurotrophin drugs will be produced and tested on a small group of 20 to 80 people for the first time to evaluate its safety. Researchers determine how best to administer the drugs to limit risks, maximize possible benefits, and identify side effects.

If proven safe in Phase I, MicroNeurotrophins will be tested for effectiveness in Phase II and Phase III, for which additional funding will be required.